FMI opines the solid oral dosage PROTAC degrader formulations was valued at USD 130 million in 2025. Demand is expected to reach USD 170 million in 2026 and USD 3.49 billion by 2036. Tablets are poised to dominate by Dosage Form with 44.0% share in 2026, and Amorphous Solid Dispersion is expected to lead by Formulation Technology through 2036.